Enterprise Europe Network

UK-based SME looking for development partners for their blood substitute product

Country of origin:
Country: 
UNITED KINGDOM
Opportunity:
External Id: 
TOUK20191206001
Published
06/12/2019
Last update
16/12/2019
Expiration date
16/12/2020

Keywords

Partner keyword: 
Emergency medicine
Medical Biomaterials
Synthetic Biology
Emergency medicine
Other clinical medicine
Other medical/health related (not elsewhere classified)
Research and experimental development on biotechnology
Other research and experimental development on natural sciences and engineering
EXPRESS YOUR INTEREST

Summary

Summary: 
A UK-based SME has developed a blood substitute based on their novel technology for self-assembly of fatty acid microparticles. The SME has shown this technology encapsulates haemoglobin and can be used in perfusion to maintain kidneys ex-vivo. The SME is looking to further develop this technology and is seeking partners with expertise in blood substitutes. It is envisaged that the partnership will take the form of a technical cooperation agreement or a license agreement.

Description

Description: 

Haemoglobin based oxygen carriers (HBOCs) have applications in wound healing, perfusion of donated transplant organs and ultimately in trauma.

The UK-based SME has, in effect, created microparticles which mimic artificial red blood cells comprised entirely of fatty acids and haemoglobin. These microparticles have the advantage that they are the same order of magnitude as red blood cells and as such do not pass through capillary walls in the same way as other HBOCs in development.

This technology needs further development towards commercialisation and the SME is looking for partners for this programme. They are especially looking for partners with expertise in HBOC development. It is expected that the partnership will take the form of a technical cooperation agreement or IP licence.

Advantages & innovations

Cooperation plus value: 
The SMEs blood substitute technology has the following advantages: Proven to efficiently oxygenate tissue enabling organs to be maintained. Can be easily and inexpensively manufactured at large scale. No issues in regards to blood type compatibility shown to date. No cultural or religious burden.

Stage of development

Cooperation stage dev stage: 
Under development/lab tested

Partner sought

Cooperation area: 
The UK SME is looking for partners in order to further develop the technology towards commercialisation. In particular they are looking for partners with expertise in the development of haemoglobin based oxygen carriers. It is envisaged that the partnership will take the form of a technical cooperation agreement or licence agreement dependent on partner circumstances.